Cellmid Ltd (CDY):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Cellmid Ltd (CDY) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C12116
◆発行会社(調査会社):GlobalData
◆発行日:2018年12月
◆ページ数:33
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cellmid Ltd (Cellmid), formerly Medical Therapies Ltd, is a life sciences company that develops and commercializes diagnostic and therapeutic products. The company holds comprehensive portfolio of intellectual property relating to the novel targets midkine and FGF5. It offers products such as midkine ELISA kit, advangen international hair loss products and evolis products. Cellmid develops CAB102, a humanized monoclonal antibody for use in solid tumors; CAB101, a monoclonal antibody for the treatment of kidney injury, and inflammatory and fibrotic diseases; and CMK103, a recombinant human form of MK protein for use in cardiac ischemia. The company markets its products in Australia and Japan. Cellmid is headquartered in Sydney, New South Wales, Australia.

Cellmid Ltd (CDY) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Cellmid Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Cellmid Ltd, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Cellmid Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Cellmid Ltd, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
Cellmid Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Cellmid Ltd, Medical Equipment, Deal Details 10
Partnerships 10
Fujikura Kasei Exercises Option For Licensing Agreement With Cellmid For Anti-Midkine Diagnostic Antibodies 10
Equity Offering 11
Cellmid Raises USD0.7 Million in Share Purchase Plan of Shares 11
Cellmid Raises USD1.3 Million in First Tranche of Private Placement of Shares 12
Cellmid to Raise USD5.4 Million in Second Tranche of Private Placement of Shares 13
Cellmid to Raise USD0.8 Million in Private Placement of Shares 14
Cellmid Raises USD3.19 Million in Private Placement of Shares 15
Cellmid Raises USD2.4 Million in First Tranche of Private Placement of Shares 16
Cellmid Completes Private Placement Of Shares For US$1.8 Million 17
Cellmid Completes Private Placement Of Shares For US$2 Million 18
Cellmid Completes Private Placement Of Shares For US$0.3 Million 19
Cellmid Ltd – Key Competitors 20
Cellmid Ltd – Key Employees 21
Cellmid Ltd – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
Jul 31, 2018: Cellmid notes to the appendix 4c–growing consumer health sales drive revenue uplift 23
Sep 27, 2017: Cellmid’s FY2017 Results Presentation 25
Corporate Communications 26
Oct 16, 2017: Cellmid Appoints Dr Martin Cross as Non-executive Director 26
Legal and Regulatory 27
Nov 02, 2018: Ikon legal action – decision handed down 27
May 29, 2018: Cellmid announces Change of Address 28
Product News 29
May 30, 2018: 5th Midkine Symposium Reinforces Clinical Potential For Cellmid’S Biotechnology Assets 29
Other Significant Developments 31
Jan 09, 2018: Cellmid Quarterly Operational Update 31
Oct 25, 2017: Cellmid: Notes to the Appendix 4C 32
Appendix 33
Methodology 33
About GlobalData 33
Contact Us 33
Disclaimer 33

List of Tables
Cellmid Ltd, Medical Equipment, Key Facts, 2018 2
Cellmid Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Cellmid Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Cellmid Ltd, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Cellmid Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Cellmid Ltd, Deals By Market, 2012 to YTD 2018 8
Cellmid Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Fujikura Kasei Exercises Option For Licensing Agreement With Cellmid For Anti-Midkine Diagnostic Antibodies 10
Cellmid Raises USD0.7 Million in Share Purchase Plan of Shares 11
Cellmid Raises USD1.3 Million in First Tranche of Private Placement of Shares 12
Cellmid to Raise USD5.4 Million in Second Tranche of Private Placement of Shares 13
Cellmid to Raise USD0.8 Million in Private Placement of Shares 14
Cellmid Raises USD3.19 Million in Private Placement of Shares 15
Cellmid Raises USD2.4 Million in First Tranche of Private Placement of Shares 16
Cellmid Completes Private Placement Of Shares For US$1.8 Million 17
Cellmid Completes Private Placement Of Shares For US$2 Million 18
Cellmid Completes Private Placement Of Shares For US$0.3 Million 19
Cellmid Ltd, Key Competitors 20
Cellmid Ltd, Key Employees 21
Cellmid Ltd, Subsidiaries 22

List of Figures
Cellmid Ltd, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Cellmid Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Cellmid Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Cellmid Ltd, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Cellmid Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Cellmid Ltd, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
Cellmid Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Cellmid Ltd, Medical Equipment, Deals by Market, 2012 to YTD 2018 8

★海外企業調査レポート[Cellmid Ltd (CDY):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • L’Occitane International SA:企業の戦略・SWOT・財務分析
    L'Occitane International SA - Strategy, SWOT and Corporate Finance Report Summary L'Occitane International SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Hwange Colliery Co Ltd:企業の戦略・SWOT・財務分析
    Hwange Colliery Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Hwange Colliery Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Cytodyn Inc (CYDY):製薬・医療:M&Aディール及び事業提携情報
    Summary Cytodyn Inc (Cytodyn) is a clinical-stage biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies t for the treatment of Human Immunodeficiency Virus (HIV) infections. The company's products pipeline include PRO 140, Cytofe …
  • Gemalto N.V. (GTO):企業の財務・戦略的SWOT分析
    Gemalto N.V. (GTO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Guizhou Space Appliance Co., Ltd.
    Guizhou Space Appliance Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Guizhou Space Appliance Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Caladrius Biosciences Inc (CLBS):企業の財務・戦略的SWOT分析
    Summary Caladrius Biosciences Inc (Caladrius), formerly NeoStem Inc, is a clinical-stage biopharmaceutical company that develops cell therapy products. The company offers multiple technology platforms targeting cardiovascular indications and autoimmune diseases. The company’s lead product CLBS03 is …
  • Alarko Holding AS (ALARK):企業の財務・戦略的SWOT分析
    Alarko Holding AS (ALARK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • UCB S.A.:企業のM&A・事業提携・投資動向
    UCB S.A. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's UCB S.A. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital …
  • Capricor Therapeutics Inc (CAPR):製薬・医療:M&Aディール及び事業提携情報
    Summary Capricor Therapeutics Inc (Capricor) is a biotechnology company that discovers, develops and commercializes biological therapeutics for the treatment of rare disorders. The company offers cardiac cell therapy and cenderitide products for the treatment of post myocardial infarction, advanced …
  • Sistema JSFC:企業の戦略・SWOT・財務情報
    Sistema JSFC - Strategy, SWOT and Corporate Finance Report Summary Sistema JSFC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Arch Pharmalabs Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Arch Pharmalabs Ltd (Arch Pharmalabs) is a healthcare products company that offers pharmaceutical ingredients. The company manufactures, develops and markets active APIs and intermediates to innovator and generic pharmaceutical players. It offers products such as docetaxel anhydrous and trih …
  • NovaBay Pharmaceuticals Inc (NBY):企業の財務・戦略的SWOT分析
    Summary NovaBay Pharmaceuticals Inc (NovaBay), formerly NovaCal Pharmaceuticals Inc is a biopharmaceutical company that discovers and develops eyecare products. The company’s products include skin and wound cleanser, daily lid and lash hygiene spray solutions, and cosetic procedures. Its daily lid a …
  • St. James’S Place Plc
    St. James'S Place Plc - Strategy, SWOT and Corporate Finance Report Summary St. James'S Place Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Amazon.com Inc (AMZN):企業の財務・戦略的SWOT分析
    Amazon.com Inc (AMZN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Celina Insurance Group:企業の戦略・SWOT・財務情報
    Celina Insurance Group - Strategy, SWOT and Corporate Finance Report Summary Celina Insurance Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Iberia Lineas Aereas De Espana, Sa:企業の戦略・SWOT・財務分析
    Iberia Lineas Aereas De Espana, Sa - Strategy, SWOT and Corporate Finance Report Summary Iberia Lineas Aereas De Espana, Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Belize Electricity Ltd:企業の発電所・SWOT分析2018
    Belize Electricity Ltd - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employ …
  • Puretech Health plc (PRTC):製薬・医療:M&Aディール及び事業提携情報
    Summary Puretech Health plc (Puretech), formerly PureTech Ventures LLC, is a biopharmaceutical company that develops medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company develops a microbiome immune system drug-discovery platform and drug ca …
  • AM Conservation Group Inc:電力:M&Aディール及び事業提携情報
    Summary AM Conservation Group Inc (AM Conservation) a subsidiary of Kohlberg & Company LLC is a clean technology company that manufactures, designs and distributes energy conservation products. The company provides products such as water conservation products, energy efficient products, energy effic …
  • Compugen Ltd (CGEN):企業の財務・戦略的SWOT分析
    Summary Compugen Ltd (Compugen) is a predictive drug discovery and development company that develops medicines for immuno-oncology and autoimmune diseases. The company’s immuno-oncology pipeline comprises COM701 and PVRIG, BAY 1905254, COM902 and TIGIT; and CGEN-XXXX/Myeloid and autoimmune diseases …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆